26 May, 2017
Several hedge funds have recently added to or reduced their stakes in HALO. 108.31 million shares or 4.02% more from 104.12 million shares in 2016Q3 were reported.
Burt Wealth Advsrs owns 901 shares for 0.01% of their portfolio. (NASDAQ:HALO). 965,000 are owned by Msd Prtn L P. Atlantic Trust Group Inc Ltd Liability reported 25,010 shares. Highbridge Capital Mngmt Limited Liability Corporation accumulated 0% or 21,770 shares. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. Proshare Advsr Lc invested in 0.01% or 103,060 shares. The Baker Bros Advisors Lp holds 1.39M shares with $13.75M value, down from 1.73M last quarter. The Shareholder Yield (Mebane Faber) of Halozyme Therapeutics, Inc. (NASDAQ:HALO). Goldman Sachs Grp Inc holds 0% in Halozyme Therapeutics, Inc. Ifc Incorporated Fl reported 81,650 shares or 0.08% of all its holdings. Senzar Asset Management Llc bought 674,900 shares as the company's stock rose 2.38% with the market. Panagora Asset Mgmt accumulated 856,007 shares or 0.04% of the stock. Wells Fargo And Co Mn holds 247,907 shares or 0% of its portfolio. (NASDAQ:HALO). The New York-based Amalgamated Bancorp has invested 0.01% in Halozyme Therapeutics, Inc. Therefore 83% are positive. The company rocked its 52-Week High of $15.2 and touched its 52-Week Low of $7.7.
Wall Street analysts expect that Halozyme Therapeutics, Inc.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, May 9th. The rating was maintained by Barclays Capital with "Overweight" on Wednesday, February 24. Halozyme Therapeutics has an average rating of "Hold" and an average price target of $13.96. The stock of Halozyme Therapeutics, Inc. Barclays Capital has "Overweight" rating and $27 target. The firm earned "Overweight" rating on Friday, September 16 by Piper Jaffray. Deutsche Bank initiated the stock with "Buy" rating in Thursday, November 3 report. The firm has "Neutral" rating by Citigroup given on Friday, January 6. The firm has "Market Outperform" rating given on Tuesday, August 11 by JMP Securities. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 44.60%.
According to the Recommendation Trends of the stock polled by Finviz, the company has a consensus recommendation of 2.3 out of the scale from 1 to 5 where 1 stands for Buy and 5 means Sell. The firm has "Market Outperform" rating by JMP Securities given on Wednesday, March 9. Synovus Financial Corp acquired a new stake in Halozyme Therapeutics during the third quarter worth about $272,000. They issued a "market perform" rating and a $14.00 price target for the company. Closing price generally refers to the last price at which a stock trades during a regular trading session.
Watching some historical volatility numbers on shares of Halozyme Therapeutics, Inc. Vale SA (ADR) (NYSE:VALE) has risen 111.11% since May 24, 2016 and is uptrending. It has outperformed by 28.19% the S&P500. The stock's market capitalization is $1.65 billion. The Company operates in research, development and commercialization of human enzymes and other drug candidates. Halozyme Therapeutics posted earnings per share of ($0.21) during the same quarter last year, which would suggest a negative year over year growth rate of 19%. Market Cap is also the figure use to determine company's size, as opposed to using sales or total asset figures. An increasing ROE indicates that a company is improving its ability to make profit without requiring as much capital. (NASDAQ:HALO) news were published by: Investorplace.com which released: "Why Foot Locker, Inc". Stifel Financial Corp purchased a new stake in Halozyme Therapeutics during the first quarter valued at approximately $187,000.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
